Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on July 8, 2019, covering events occurring on July 1, 2019. The filing addresses a significant change in corporate governance and management involving the departure of the former President and Chief Executive Officer, William Annett.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics. The only specific financial data disclosed relates to the compensation and transition package for the departing executive:
- Severance Cash Payment: $210,000.
- Accrued Salary: Payment of accrued but unpaid salary through June 30, 2019.
- Prorated Bonus: A portion of the target bonus for the period January 1 through June 30, 2019.
- Consulting Fee: $35,000 per month for services provided through August 31, 2019.
- Benefits: Accrued vacation pay, vested retirement/equity benefits, and up to six months of COBRA health coverage premiums paid by the company.
Material Changes
The primary material change reported is the departure of William Annett as President and CEO. A Transition Agreement was executed to facilitate his exit and subsequent consulting role. Key terms include:
- Consulting Period: Mr. Annett will provide consulting services through August 31, 2019, with potential month-to-month extensions through December 31, 2019, subject to mutual agreement.
- Equity Vesting: Unvested stock options will continue to vest during the consulting period. Upon completion, unvested options will vest as if he had continued service for an additional six months, subject to performance milestones for performance-based options.
- Option Exercise Period: The post-employment exercise period for vested options is extended until one year after the end of the consulting period.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook for the company. It includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially from anticipated results due to risk factors detailed in the company's most recent Form 10-K. The filing does not disclose any new contingencies or unusual items beyond the executive transition.
Investor Verification Checklist
- Verify the identity and background of the newly appointed Chief Executive Officer to replace William Annett.
- Review the full text of the Transition Agreement (Exhibit 10.1) for specific performance milestones tied to equity vesting.
- Confirm the total cash outflow impact of the severance and consulting fees on the company's current liquidity position.
- Check subsequent filings for any updates on the consulting arrangement beyond the initial August 31, 2019, date.